CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
October 26 2022 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
leveraging the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases, announced today
that the company will release its 2022 third quarter financial
results after the market closes on Tuesday, November 8, 2022.
Management will host a conference call and webcast at 5:00 p.m. ET
(2:00 p.m. PT) on the same day to provide an update on the
company’s business.
Details for the Conference Call: Date: November
8, 2022Time: 5:00 p.m. ET (2:00 p.m. PT)
Conference Audio
- Dial-in U.S. and Canada: (855) 560-2576
- Dial-in International: (412) 317-5242
- Conference ID No.: 10171343
Webcast
- A simultaneous webcast of the call will be accessible via the
Investors section of the CohBar website at www.cohbar.com.
For individuals participating in the Investor Call or webcast,
please call or login to the conference audio approximately 10
minutes prior to its start.
An audio replay of the call will be available beginning at 8:00
p.m. Eastern Time on November 8, 2022, through 11:59 p.m. Eastern
Time on November 29, 2022. To access the recording please dial
(844) 512-2921 in the U.S. and Canada, or (412) 317-6671
internationally, and reference Conference ID# 10171343. The audio
recording will also be available at www.cohbar.com during the same
period.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company
leveraging the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases with limited to no
treatment options. CohBar has assembled a leading position in
exploring the mitochondrial genome and its utility for the
development of novel therapeutics, including world-renowned
expertise in mitochondrial biology, a broad intellectual property
estate, key opinion leaders and disciplined drug discovery and
development processes. CohBar is utilizing its Mito+ platform to
identify and develop modified versions of natural peptides called
analogs to treat a variety of serious conditions, with a focus on
diseases involving inflammation and fibrosis. CohBar is planning to
file an IND for its second clinical candidate CB5138-3 in the
second half of 2023, with an initial indication of idiopathic
pulmonary fibrosis. The company has previously demonstrated
clinical proof of concept for its approach with the positive
topline data from its CB4211 product candidate being developed for
NASH and obesity.
For additional company information, please visit www.cohbar.com
and engage with us on LinkedIn.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Aug 2024 to Sep 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Sep 2023 to Sep 2024